A Study of AMDX-2011P in Participants With Alzheimer's Disease

Inclusion Criteria:

1. Confirmed diagnosis of Alzheimer's Disease (AD) with documented positive amyloidbeta signal via positron emission tomography (PET) brain scan

2. Must be willing to consent to genotyping for apolipoprotein E (APOE)

3. Ability to fixate and undergo retinal imaging of both eyes

Exclusion Criteria:

1. Presence of any underlying physical or psychological medical condition that, in theopinion of the investigator, would make it unlikely that the participant willcomplete the study per protocol

2. Diagnosis of glaucoma, or suspect of having glaucoma in either eye as determined byan ophthalmologist as a clinical investigator, based on results from the eyeexamination, visual field, and/or optical coherence tomography (OCT) results

3. Diagnosis of intermediate dry, wet/neovascular, or geographic atrophy forms ofage-related macular degeneration (AMD) in either eye, OR as determined by anophthalmologist as a clinical investigator, based on results from the eyeexamination and/or optical coherence tomography (OCT) results

4. Clinically significant laboratory abnormalities as assessed by the investigator

5. Prolonged QTcF (corrected QT interval by Fridericia method) (>450 ms for males and >470 ms for females), cardiac arrhythmia, or any clinically significant abnormalityin the resting electrocardiogram (ECG), as judged by the investigator.